Apellis Pharmaceuticals Inc at Goldman Sachs Healthcare C-Suite Unscripted Conference Transcript
Thank you so much, everyone, for joining us. Really pleased to have with us for the next panel, Timothy Sullivan, Chief Financial Officer of Apellis and also on stage is Elizabeth Webster, who's part of the biotechnology team covering Apellis here. To start, Tim, thank you so much for joining us. And can you give us a snapshot of where the company stands today, and what your strategic priorities are for 2024?
Yes, sure. So thank you, Salveen, for having us in Goldman. So Apellis was really built on the philosophy of controlling complement Factor III. So complement, as you may know, is the ancient part of our immune system. And really, that's only recently in the last sort of 20 years, become an area for a focus for drug development, starting with Soliris and Alexion for PNH. We always had the philosophy and this was laid out by Cedric many years ago, controlling complement Factor III would kind of be the Swiss Army
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |